Can biotechs keep up with rising demand?

A rise in off-label uses of GLP-1 therapies for weight loss is causing shortages, particularly among people without obesity or related health issues. The biotech industry is responding by investing in manufacturing capacity and new therapeutic options. Europharma company Corden Pharma aims to speed up GLP-1 production with a €900m investment, Eli Lilly plans to ramp up production at its newly-acquired Nexus Pharmaceuticals’ site, and Danish multinational Novo Nordisk is investing $4bn in a North Carolina facility.